A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-lb in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis

Information on the cost utility of interferon beta-lb and mitoxantrone hydrochloride, 2 disease-modifying agents approved by the US Food and Drug Administration for the treatment of secondary progressive (SP) multiple sclerosis (MS), is limited. The aim of this study was to compare the cost utility...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical therapeutics 2003-02, Vol.25 (2), p.611-634
Hauptverfasser:	Touchette, Daniel R., Durgin, Tracy L., Wanke, Lee A., Goodkin, Donald E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Autoimmune diseases Cost analysis cost utility cost-effectiveness Health care Interferon Markov analysis Markov chains mitoxantrone hydrochloride Monte Carlo simulation Multiple sclerosis Pharmacoeconomics Preventive medicine Quality of life Sensitivity analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!